Back to top
more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$63.93 USD

63.93
353,481

+2.52 (4.10%)

Updated May 3, 2019 04:00 PM ET

After-Market: $64.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[MRTX]

Reports for Purchase

Showing records 81 - 100 ( 156 total )

Industry: Medical - Biomedical and Genetics

Record: 81

02/28/2020

Company Report

Pages: 8

4Q19 Results-MRTX849 KRYSTAL Trial Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 82

01/24/2020

Company Report

Pages: 7

Mirati Common Stock Offering Closed; Raising PT to $134

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 83

12/13/2019

Daily Note

Pages: 3

BeiGene Announces Phase 1b Data for Sitravatinib Plus Tislelizumab

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 84

11/11/2019

Company Report

Pages: 8

Positive Interim Sitravatinib Data Presented at SITC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 85

11/06/2019

Company Report

Pages: 8

3Q19 Results; All Eyes on MRTX849; Interim Phase 2 Sitravatinib Data at SITC This Weekend

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 86

10/29/2019

Company Report

Pages: 8

Initial MRTX849 Data Impressive in Our Opinion

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 87

10/17/2019

Daily Note

Pages: 4

Mirati to Present MRTX849 Data at ACR-NCI-EORTC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 88

08/06/2019

Company Report

Pages: 8

2Q19 Results; KRAS Taking Center Stage but Do Not Forget Sitravatinib

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 89

06/05/2019

Company Report

Pages: 8

AMG 510 Data at ASCO Gives Us More Confidence in MRTX849; Raising Our PT to $117

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 90

05/01/2019

Company Report

Pages: 8

Reports 1Q19 Results; Development of Sitravatinib and MRTX849 Remain on Track; Lowering PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 91

03/01/2019

Company Report

Pages: 8

Mirati Reports 4Q18 Results; Combination Trials and Pipeline Progress

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 92

02/15/2019

Company Report

Pages: 8

Mirati Therapeutics Model Update; Raising PT to $85

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 93

01/16/2019

Daily Note

Pages: 3

First Patient Dosed in MRTX849 Phase 1/2 Trial in Solid Tumor Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 94

01/08/2019

Company Report

Pages: 8

Bristol-Myers Squibb Collaboration for Sitravatinib Phase 3 Combo Trial in NSCLC Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 95

11/30/2018

Daily Note

Pages: 3

FDA Clears IND Application for MRTX849 Phase 1/2 Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 96

11/12/2018

Company Report

Pages: 8

Mirati Presents Mocetinostat and Sitravatinib NSCLC Data at SITC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 97

11/07/2018

Company Report

Pages: 8

Mirati 3Q18 Results; Continued Progress With Sitravatinib and MRTX849

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 98

10/30/2018

Daily Note

Pages: 3

Mirati Announces KRAS IND Submission for Potential Development in NSCLC and Colorectal Cancer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 99

10/23/2018

Company Report

Pages: 8

Mirati Therapeutics Presents Positive Data on Sitravatinib in NSCLC at ESMO

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 100

08/02/2018

Company Report

Pages: 8

2Q18 Results: Raising Price Target to $65

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party
// eof